Taconic_Logo_Vert_Process_Medium resize.jpg
Taconic Biosciences Expands Immuno-oncology Animal Model Portfolio
January 18, 2021 09:00 ET | Taconic Biosciences
RENSSELAER, N.Y., Jan. 18, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology...
Cellectis Logo.png
Monthly information on share capital and company voting rights
January 06, 2021 16:30 ET | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Appointment of William C. Roberts as Vice President, Investor Relations & Corporate Communications
January 04, 2021 07:00 ET | G1 Therapeutics
- Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage...
lsif-logo-default (1).png
Life Sciences Company Investor Presentations Now Available for On-Demand Viewing
December 21, 2020 08:35 ET | Life Sciences Investor Forum
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the December 17th conference are now available for on-demand viewing at...
lsif-logo-default (1).png
Virtual Conference for Life Sciences Companies Broadcast Live December 17th, 2020
December 14, 2020 08:29 ET | Life Sciences Investor Forum
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals...
lsif-logo-default (1).png
Caladrius Biosciences to Webcast Live at Life Sciences Investor Forum
December 10, 2020 08:30 ET | Life Sciences Investor Forum
BASKING RIDGE, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Arbutus Biopharma Logo
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
December 10, 2020 07:30 ET | Arbutus Biopharma Corporation
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks (–1.44 log10, N=7, p<0.7) AB-729 remains generally safe...
Cellectis Logo.png
Monthly information on share capital and company voting rights
December 08, 2020 16:30 ET | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
ibn-iw-globe-2.png
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein
November 24, 2020 08:17 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Cellectis Logo.png
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma
November 17, 2020 20:00 ET | Cellectis Inc.
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...